VIDEO: Optogenetic therapy represents ‘completely different approach to GA’

In this video from the Macula Society meeting, Theodore Leng, MD, FACS, discusses MCO-010, an optogenetic therapy from Nanoscope Therapeutics under study for advanced retinitis pigmentosa and geographic atrophy.
“This program is actually planning to launch a phase 2 trial for GA in 2026,” Leng, professor of ophthalmology and director of clinical and translational research at Byers Eye Institute, Stanford University, said. “I think this represents a completely different approach to GA, shifting from slowing disease progression via the complement inhibition to potentially








